GSE119345 bexarotene T cell 2 v 4 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE119345_bexarotene_T cell_2_v_4_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE119345_bexarotene_T cell_2_v_4_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE119345_bexarotene_T cell_2_v_4_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE119345_bexarotene_T cell_2_v_4_human_up.

Results found

Linked to

 

Label

Description

 

Gene

MIR4435-2 host gene

Gene

cytoskeleton regulator RNA

Gene

PDCD6IP pseudogene 2

Gene

HECW2 antisense RNA 1

Gene

RNA component of signal recognition particle 7SL1

Gene

long intergenic non-protein coding RNA 2982

Gene

long intergenic non-protein coding RNA 2611

Gene

long intergenic non-protein coding RNA 996

Gene

uncharacterized LOC105369329

Gene

long intergenic non-protein coding RNA 1505


  • Gene

    cytoskeleton regulator RNA


  • Gene

    PDCD6IP pseudogene 2


  • Gene

    HECW2 antisense RNA 1


  • Gene

    RNA component of signal recognition particle 7SL1


  • Gene

    long intergenic non-protein coding RNA 2982


  • Gene

    long intergenic non-protein coding RNA 2611


  • Gene

    long intergenic non-protein coding RNA 996


  • Gene

    uncharacterized LOC105369329


  • Gene

    long intergenic non-protein coding RNA 1505

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.